| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
Phathom Pharmaceuticals, Inc.$12.61
+0.37 (+3.04%)
C 41Pipeline Score Overvalued Pharma · Commercial
Market Cap
903.63 M
EPS
-2.11
P/E Ratio
-
Value Trade
20.38 M
SEC Financials
Q1 2026Dilution Risk
Revenue
58.30 M
R&D Expenses
7.77 M
Operating CF
-15.65 M
Total Assets
305.12 M
Total Liabilities
642.08 M
Equity
-336.95 M
D/E Ratio
12,345
-11.55 %
Week
-13.11 %
1 Month
-4.79 %
3 Month
-20.66 %
6 Month
-68.01 %
5 Year
-49.64 %
All Time
Cash Data
Cash Position
180.90 M
Monthly Burn
5.22 M
Runway
32.6 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
2.32 M
52 Week Range
3.92 - 18.31
% held by Insiders
36.93 %
% held by Institutions
54.14 %
Enterprise Value
1.27 B
Total Shares
79.74 M
Short %
22.19 %
Float Shares
43.38 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Phathom Pharmaceuticals, Inc.
330Total events
3Upcoming
80Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 3
Event history 327
Q3 2026
▲Timing GuidancePresentation
Operating profitability expected beginning Q3 2026 and for FY 2026
Jun 23, 2026
▲Enrollment CompleteVOQUEZNAApprovedTrial
Completed patient enrollment in Phase 2 pHalcon-EoE-201 study of VOQUEZNA in EoE
eosinophilic esophagitis (EoE)source ↗
Jun 9, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat
Jun 3, 2026
May 28, 2026
May 4, 2026
◆Oral PresentationVOQUEZNAApprovedPresentation
Product theater presentation on VOQUEZNA at DDW 2026
Gastroesophageal Reflux Disease (GERD)source ↗
May 2, 2026
◆Poster PresentationVOQUEZNAApprovedPresentation
Three poster presentations on VOQUEZNA at DDW 2026
Gastroesophageal Reflux Disease (GERD)source ↗
May 2, 2026
▲Poster PresentationVonoprazanApprovedPresentation
Phathom-sponsored analysis of heartburn and regurgitation from pHalcon-NERD-301 recognized as Poster of Distinction
Non-Erosive GERDsource ↗
Apr 30, 2026
Apr 30, 2026
▲Enrollment UpdateVOQUEZNAApprovedTrial
Phase 2 pHalcon-EoE-201 trial enrolling ahead of schedule
eosinophilic esophagitis (EoE)source ↗
Apr 15, 2026
◆Oral PresentationPresentation
Fireside Chat at 25th Annual Needham Virtual Healthcare Conference
Drug Pipeline Intelligence
C41
Pipeline Score $248M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.3x
rNPV / MCap Top 59%
Micro Cap (rank 375 of 911)
Percentile RankPhathom Pharmaceuticals, Inc. carries a moderate pipeline score (41/100), with $621M risk-adjusted pipeline value, led by Vonoprazan in Erosive Esophagitis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vonoprazan Small molecule | Erosive Esophagitis | Phase 3 | NCT06391177 | 50% | $551M | COMPLETED | 1,042 | - | - | Sep 19, 2024 | - | Mar 25, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
vonoprazan | GERD, H. pylori eradication | Phase 3 | 2026-05-20 | Meta-analysis of data from randomized controlled trials evaluating healing outcomes in patients with severe (LA Grade C and D) erosive esophagitis (Erosive GERD) treated with vonoprazan compared to the proton pump inhibitor (PPI) lansoprazole Read More | Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting Read More | |
vonoprazan | GERD, H. pylori eradication | Phase 3 | 2026-05-20 | Meta-analysis of data from randomized controlled trials evaluating healing outcomes in patients with severe (LA Grade C and D) erosive esophagitis (Erosive GERD) treated with vonoprazan compared to the proton pump inhibitor (PPI) lansoprazole Read More | Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting Read More | |
vonoprazan | GERD, H. pylori eradication | Phase 3 | 2026-05-20 | Meta-analysis of data from randomized controlled trials evaluating healing outcomes in patients with severe (LA Grade C and D) erosive esophagitis (Erosive GERD) treated with vonoprazan compared to the proton pump inhibitor (PPI) lansoprazole Read More | Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PHAT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PHAT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PHATPhathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Phathom Pharmaceuticals has successfully completed patient enrollment in its Phase 2 pHalcon-EoE-201 study of VOQUEZNA (vonoprazan) for treating eosinophilic esophagitis (EoE). The trial, which is the first large placebo-controlled study for acid suppression treatment in EoE, enrolled 95 patients across 41 U.S. sites. Topline results are anticipated in the fourth quarter of 2026.
Read more →PHATPhathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals, Inc. has announced its upcoming participation in several investor conferences scheduled for May and June 2026. The management team will engage in one-on-one meetings and participate in fireside chats at notable events, including the Craig-Hallum 23rd Annual Institutional Investor Conference and the Jefferies Global Healthcare Conference. This involvement highlights the company's focus on gastrointestinal diseases and its interest in enhancing shareholder relations and securing further investment.
Read more →PHATPhathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Phathom Pharmaceuticals showcased extensive research on vonoprazan at the Digestive Disease Week 2026. A total of 31 abstracts, including 28 independent studies, highlighted its efficacy in treating conditions like GERD and H. pylori eradication. Notably, a Phathom-sponsored analysis received a Poster of Distinction, reflecting the growing interest in vonoprazan's applications in GI medicine.
Read more →PHAT▲ +7.2%on this news
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
Phathom Pharmaceuticals will showcase VOQUEZNA (vonoprazan) at the DDW 2026 annual meeting in Chicago, scheduled for May 2-5. The company plans to conduct a product theater presentation and share clinical and real-world data through poster presentations. CEO Steve Basta emphasized the importance of this event for connecting with the GI community and advancing GERD treatment.
Read more →PHATPhathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals reported a strong financial performance for Q1 2026, with net revenues reaching $58.3 million, a 104% increase compared to the previous year. The company is maintaining its guidance for the full year, anticipating operating profitability starting in Q3 2026. Prescription growth for VOQUEZNA has been robust, with 1.35 million prescriptions filled to date, indicating positive momentum in the gastrointestinal market.
Read more →PHATPhathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
Phathom Pharmaceuticals will host a conference call on April 30, 2026, to report its first quarter financial results and provide a business update. The call will be accessible via a live webcast, with a recording available for 90 days afterward. The company continues to focus on its gastrointestinal treatments, particularly the marketed drug vonoprazan.
Read more →PHAT▲ +10.1%on this news
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Phathom Pharmaceuticals reported strong financial results for Q4 and full year 2025, highlighting significant revenue growth and a realigned sales organization. The company anticipates operating profitability by Q3 2026 and cash flow positivity by 2027. However, they face challenges such as high operating expenses and market acceptance of their product VOQUEZNA.
Read more →PHAT▲ +6.2%on this news
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
Phathom Pharmaceuticals will host a live webcast on February 26, 2026, to discuss its fourth quarter and full year 2025 financial results. The event will also provide a business update. Phathom is known for its focus on gastrointestinal diseases and markets vonoprazan, a first-in-class potassium-competitive acid blocker.
Read more →PHAT▼ -6.2%on this news
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Phathom Pharmaceuticals will present at the Guggenheim Emerging Outlook Biotech Summit 2026, with a fireside chat scheduled for February 12. The conference will take place in New York from February 11-12, and management will also hold one-on-one meetings. The event will be accessible via a live webcast and archived recordings.
Read more →PHAT▼ -13.7%on this news
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
Phathom Pharmaceuticals has announced the pricing of a public offering, aiming to raise approximately $130 million through the sale of 6,875,000 shares of common stock and pre-funded warrants. The shares will be offered at $16.00 each and the launch is subject to customary closing conditions, with expected closure around January 9, 2026. The net proceeds are intended for general corporate purposes, including research and development, which aligns with the company's focus on novel GI treatments.
Read more →PHAT▲ +10.4%on this newsshared move
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Phathom Pharmaceuticals has announced preliminary unaudited financial results for the fourth quarter and full year of 2025, highlighting a significant milestone with 1 million prescriptions for its product VOQUEZNA. The company aims to achieve operating profitability in the second half of 2026. However, these preliminary results are subject to audit, and actual performance may vary. Potential risks include market acceptance challenges and a smaller market opportunity for their product than anticipated.
Read more →PHAT▲ +10.4%on this newsshared move
FLORHAM PARK, N.J.
Phathom Pharmaceuticals, Inc. announced plans for a public offering of its common stock or pre-funded warrants, dependent on market conditions. The underwriters will have a 30-day option to purchase additional shares, but there are uncertainties regarding the completion and terms of this offering. The proceeds from this public offering are intended for general corporate purposes, including research and development. The company continues to market its product VOQUEZNA for various gastrointestinal conditions.
Read more →PHAT▲ +10.4%on this newsshared move
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Phathom Pharmaceuticals has announced a proposed public offering of common stock and pre-funded warrants aimed at raising capital. This offering will be used for general corporate purposes, including research, development, and working capital. With Guggenheim Securities and Cantor acting as joint bookrunning managers, the company has filed a registration statement with the SEC to facilitate the offering. However, there are uncertainties related to market conditions and the final terms of the offering.
Read more →PHATPhathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Phathom Pharmaceuticals has initiated the Phase 2 pHalcon-EoE-201 clinical trial for VOQUEZNA (vonoprazan), targeting eosinophilic esophagitis (EoE) in adults. The trial aims to evaluate the efficacy of VOQUEZNA as a treatment option, addressing significant unmet needs in EoE management. The study will enroll 80 adults and is expected to yield results by 2027.
Read more →PHATPhathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Phathom Pharmaceuticals reported positive financial results for Q3 2025, highlighting revenue growth and effective cost management. The company is focused on enhancing its market presence with VOQUEZNA tablets, engaging gastroenterologists to drive sales. Despite the optimistic outlook, there are concerns regarding market acceptance and competition that could impact future performance.
Read more →PHATPhathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
Phathom Pharmaceuticals announced the publication of data from its Phase 3 pHalcon-NERD-301 study, which demonstrated that VOQUEZNA (vonoprazan) significantly improves nocturnal symptoms in patients with Non-Erosive Reflux Disease (NERD). The study involved 772 patients and revealed that nighttime GERD symptoms, affecting up to 80% of patients, can be effectively managed with VOQUEZNA. This publication underscores the importance of addressing nighttime symptoms, which are often inadequately treated with existing therapies.
Read more →PHATPhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
Phathom Pharmaceuticals will participate in the ACG 2025 Annual Scientific Meeting, showcasing VOQUEZNA (vonoprazan) as a treatment for GERD. The company aims to connect with the GI community, sharing insights and reinforcing its commitment to improving patient outcomes. The event will feature a product theater presentation and an independent medical education program on GERD management.
Read more →PHAT▲ +8.1%on this newsshared move
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
Phathom Pharmaceuticals, a biopharmaceutical company specializing in gastrointestinal treatments, has announced plans to host a live webcast on October 30, 2025, to report its third quarter financial results and provide a business update. The webcast will be accessible on their website and will allow stakeholders to stay informed about the company's performance and future strategies. Phathom's primary product, vonoprazan, is currently marketed in the U.S. for various gastrointestinal conditions.
Read more →PHATPhathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
Phathom Pharmaceuticals has appointed Sanjeev Narula as Chief Financial and Business Officer. Narula brings extensive experience from his previous roles, including CFO at Intra-Cellular Therapies. His appointment comes as Phathom seeks to enhance its financial performance and capitalize on the growth of its product VOQUEZNA, which is aimed at treating gastrointestinal diseases.
Read more →PHATPhathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
Phathom Pharmaceuticals has clarified that an upcoming Schedule 13D filing by Frazier Life Sciences will reflect administrative changes in reporting but will not indicate a decrease in ownership for any Frazier fund or individual. The adjustments are intended to enhance clarity regarding holdings without any sale of shares. This announcement aims to reassure stakeholders about the stability of ownership.
Read more →PHAT▲ +8.3%on this news· ran to +20% by day 3
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Over 580,000 VOQUEZNA prescriptions filled to date, reflecting 49% growth since last earnings report Net revenues of $39
Phathom Pharmaceuticals, Inc. reported its second quarter 2025 financial results, revealing over 580,000 prescriptions for VOQUEZNA, which reflects a 49% growth from the previous quarter. The company reported net revenues of $39 million and aims for profitable growth by 2026, focusing on high-value prescribers and strategic cost reductions. Despite this positive outlook, concerns remain regarding the commercialization challenges and market acceptance of VOQUEZNA, along with competitive pressures that may impact its success.
Read more →PHAT▼ -8.6%on this news
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
Phathom Pharmaceuticals will host a live webcast on August 7, 2025, at 8:00 am EDT to report its second quarter financial results and provide a business update. This event marks an important occasion for the company, which is dedicated to developing and commercializing innovative treatments for gastrointestinal diseases. Included in its portfolio is vonoprazan, used for various gastrointestinal conditions. A recording of the presentation will be available for 90 days after the live event.
Read more →PHAT▼ -9.1%on this news
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
Phathom Pharmaceuticals has appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary. Cook has extensive experience in pharmaceutical law, having previously served as Senior Vice President and General Counsel at Sage Therapeutics. In her new role, she is expected to play a crucial part in shaping Phathom's corporate strategy during a vital phase of the company's development. The company aims to enhance treatment standards in gastrointestinal diseases, particularly with its product vonoprazan.
Read more →PHAT▼ -9.1%on this news
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Phathom Pharmaceuticals announced the approval of inducement awards for Anne Marie Cook, who has been appointed as the Chief Legal Officer and Corporate Secretary. The awards include a stock option to purchase 210,000 shares and 50,400 performance stock units, with vesting schedules linked to company performance and continued service. These grants are made in accordance with Nasdaq Listing Rule 5635(c)(4), indicating a strategic move to attract and retain key talent. Phathom continues to focus on developing innovative treatments for gastrointestinal diseases.
Read more →PHATPhathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets Through May 3, 2032
Phathom Pharmaceuticals announced that the FDA has updated the Orange Book to reflect a full 10-year period of non-patent exclusivity for its product VOQUEZNA (vonoprazan) through May 3, 2032. This correction aligns with regulatory requirements and emphasizes the product’s long-term commercial viability. VOQUEZNA is a first-in-class medication for treating various gastrointestinal conditions, including GERD and H. pylori infections. By securing this exclusivity, Phathom solidifies its market presence in the healthcare industry focused on GI treatments.
Read more →PHAT▲ +90.2%on this news
Terrie Curran Chief Executive Officer Phathom Pharmaceuticals, Inc. 100 Campus Drive, Suite 102 Florham Park, NJ 07932
Phathom Pharmaceuticals received favorable news as the FDA granted its petition to correct the Orange Book listing for its drug Voquezna, allowing it to benefit from a total of 10 years of non-patent new chemical entity (NCE) exclusivity. This exclusivity was extended due to the drug's active moiety, vonoprazan, which has already been recognized as a new chemical entity. The FDA acknowledged the validity of Phathom's arguments regarding the exclusivity provisions under the Hatch-Waxman Amendments, which promote pharmaceutical innovation.
Read more →PHAT▲ +90.2%on this news
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032
Phathom Pharmaceuticals has received FDA approval for its Citizen Petition, confirming 10 years of regulatory exclusivity for VOQUEZNA (vonoprazan) tablets, extending this exclusivity until May 3, 2032. This decision is significant as it provides a competitive edge for Phathom in the gastrointestinal treatment market. The company focuses on developing innovative therapies for gastrointestinal diseases, with its primary product, VOQUEZNA, addressing heartburn and H. pylori infections. The FDA's recognition is anticipated to enhance the commercialization potential for Phathom's offerings.
Read more →PHAT▼ -21.7%on this news· ran to -44% by day 3
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare
Phathom Pharmaceuticals has reported its financial results for the first quarter of 2025, highlighting significant progress in the launch of its drug VOQUEZNA, which has reached over 390,000 prescriptions. To navigate a challenging financial landscape, the company is implementing strategic cost reductions, including a 6% reduction in its workforce and other operational changes expected to save $60 to $70 million. Despite these challenges, Phathom aims to achieve profitability from operations by 2026 while maintaining the strength of its sales force.
Read more →PHATPhathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2025 Annual Meeting
Phathom Pharmaceuticals announced the presentation of real-world data for its treatment VOQUEZNA (vonoprazan) at the Digestive Disease Week 2025. This data focuses on GERD patients in the U.S. and highlights how VOQUEZNA serves as an effective treatment option for those inadequately managed by proton pump inhibitors. The company will present key findings on May 5, 2025, alongside hosting a Product Theater to inform healthcare professionals about VOQUEZNA's clinical utility. Despite its benefits, the treatment comes with potential risks that need careful consideration.
Read more →PHATPhathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
Phathom Pharmaceuticals, Inc. announced it will host a live webcast on May 1, 2025, to report its first quarter 2025 financial results and provide a business update. The event will commence at 8:00 am EDT and will be accessible via their website. Phathom focuses on developing novel treatments for gastrointestinal diseases, notably marketing vanoprazan to help relieve conditions such as heartburn and H. pylori infection.
Read more →PHAT▼ -11.4%on this news
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
Phathom Pharmaceuticals has appointed Ted Schroeder to its Board of Directors, recognizing his extensive experience in leading biopharma companies. With a proven history of commercialization and strategic business guidance, he is expected to provide valuable insights during this critical time for Phathom. This appointment aligns with the company's ongoing efforts to enhance the market presence of its first-in-class therapies, particularly VOQUEZNA® for gastrointestinal diseases.
Read more →PHAT▼ -8.8%on this news· ran to -23% by day 3
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Phathom Pharmaceuticals has announced that its management team will participate in a fireside chat at the upcoming 24th Annual Needham Virtual Healthcare Conference scheduled for April 8, 2025. The company will also engage in one-on-one meetings throughout the conference from April 7-10, 2025. Attendees can access the live webcast and archived recording through Phathom's website. Phathom focuses on developing treatments for gastrointestinal diseases, notably showcasing their offerings that include vonoprazan for treating GERD and H. pylori infection.
Read more →PHAT▼ -18.3%on this newsshared move
Phathom Pharmaceuticals Announces Leadership Succession
Phathom Pharmaceuticals has announced the immediate appointment of Steven Basta as President and CEO, succeeding Terrie Curran who stepped down for personal reasons. The Board of Directors expressed confidence in Basta's leadership and experience as crucial for accelerating the company's growth, particularly regarding its product VOQUEZNA. The press release also highlighted forward-looking statements regarding the company's commercial strategies and potential market challenges that could affect their plans.
Read more →PHATPhathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update VOQUEZNA (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven
Phathom Pharmaceuticals reported strong financial results for the fourth quarter and full year of 2024, highlighted by $55.3 million in revenues from its drug VOQUEZNA. The company is experiencing notable momentum driven by successful commercial strategies, a direct-to-consumer campaign yielding positive engagement, and growing prescriber adoption. Despite these achievements, challenges include navigating regulatory uncertainties and dependency on third-party manufacturing and clinical testing. Phathom remains focused on sustaining growth and achieving long-term success in the gastrointestinal treatment market.
Read more →PHAT▼ -5.8%on this news
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
Phathom Pharmaceuticals, Inc. has announced a live webcast scheduled for March 6, 2025, at 8:30 am ET to present its fourth quarter and full year 2024 financial results alongside a business update. The company specializes in developing novel treatments for gastrointestinal diseases, particularly through its product vonoprazan. This webcast will provide investors and stakeholders insight into the company's financial health and future strategies. The event will also be available for later viewing for 90 days post-presentation.
Read more →PHATPhathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
Phathom Pharmaceuticals announced that its management team will participate in the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025. They will engage in a fireside chat and one-on-one meetings during the event, which aims to foster investor relations. The company is known for developing treatments for gastrointestinal diseases, including vonoprazan, marketed under the brand VOQUEZNA® for various conditions. Attendees can view the webcast from the event through the company’s website.
Read more →PHAT▼ -6%on this news
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA (vonoprazan) Tablets
Phathom Pharmaceuticals has submitted a Citizen Petition to the FDA seeking to correct the Orange Book listings for its VOQUEZNA (vonoprazan) tablets to reflect the full 10-year New Chemical Entity exclusivity period, expiring on May 3, 2032. The company argues that this exclusivity is crucial for all vonoprazan-based products and is supported by the GAIN Act. Phathom believes that this update is necessary to align the listings with the legal protections granted to similar products. The FDA is required to respond to the petition within 180 days.
Read more →PHATPhathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, ov
Phathom Pharmaceuticals reported its third quarter 2024 financial results, showcasing net revenues of $16.4 million, significantly up from $7.3 million in the previous quarter. The company highlighted robust demand for its VOQUEZNA treatment, which has been favorably received by physicians, with expanded commercial coverage reaching over 120 million U.S. lives. Despite the positive sales momentum and a successful $130 million equity raise, Phathom continues to face substantial operating losses and the inherent risks in the commercialization of its products. Management remains optimistic about overcoming these challenges and capturing market share in gastrointestinal treatments.
Read more →PHAT▲ +8.3%on this news
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
Phathom Pharmaceuticals, Inc. announced it will report its third quarter 2024 financial results and provide a business update on November 7, 2024. The company will host a live webcast at 8:30 am ET, and a recording will be made available for 90 days. Phathom focuses on novel treatments for gastrointestinal diseases, including products based on its exclusive rights to vonoprazan. More details about the event can be found on the company's website.
Read more →PHAT▲ +8.3%on this newsshared move
Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
Phathom Pharmaceuticals announced that it will present data for VOQUEZNA at the ACG 2024 Annual Scientific Meeting. The presentation will highlight results from the PHALCON-NERD-201 trial, which evaluated an On-Demand dosing regimen for the treatment of Non-Erosive GERD. The study demonstrated that VOQUEZNA provided significant relief for heartburn symptoms, with data recognized by the ACG with an Outstanding Research Award. Physicians are optimistic about VOQUEZNA's potential benefits, particularly with this new dosing option.
Read more →PHATPhathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants Florham Park, N.J.
Phathom Pharmaceuticals has announced the pricing of its underwritten offering of common stock and pre-funded warrants, raising approximately $130 million. The shares are being sold at $11.50 each, and the offering is expected to close by August 20, 2024. Proceeds will be utilized for commercialization expenses, further clinical development of vonoprazan, and general corporate purposes. The company emphasizes that the offering's completion is subject to customary closing conditions, amidst inherent risks.
Read more →PHAT▲ +8.7%on this news
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Over 122,000 prescriptions for VOQUEZNA products written by healthcare providers, launch to date, a 184% increase since l
Phathom Pharmaceuticals has reported its financial results for the second quarter of 2024, highlighting a remarkable 184% increase in prescriptions for its VOQUEZNA gastrointestinal treatment. With FDA approval and expanded labeling, the company is focused on promoting VOQUEZNA to healthcare providers and patients alike. The financial overview shows significant operating losses, particularly in R&D and operational expenses, raising concerns about sustainability. Despite these challenges, the company is optimistic about building VOQUEZNA into a blockbuster treatment.
Read more →PHATPhathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
Phathom Pharmaceuticals announced that CVS Caremark has added VOQUEZNA (vonoprazan) tablets to its commercial formularies for its over 26 million commercially insured members. This development grants access to VOQUEZNA for more than 116 million covered lives, marking a significant advancement in GERD treatment. Phathom is also implementing savings programs to assist eligible patients facing coverage challenges, which reflects their commitment to patient access and treatment options for acid-related disorders.
Read more →PHATPhathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
Phathom Pharmaceuticals, Inc. will report its second quarter 2024 financial results on August 8, 2024, during a live conference call at 8:30 am ET. The company, focused on developing treatments for gastrointestinal diseases, will also provide updates on business progress during the call. Details of the webcast will be accessible on the Phathom website, with recordings available afterward.
Read more →PHAT▼ -7.7%on this news
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
Phathom Pharmaceuticals has announced that the FDA has approved VOQUEZNA (vonoprazan) tablets for relieving heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (GERD) in adults. This marks the first new class of treatment for GERD in over three decades. The approval is based on positive results from the Phase 3 PHALCON-NERD-301 trial, which showed significant reductions in heartburn episodes. While VOQUEZNA provides an innovative treatment option, some common side effects have been reported among patients.
Read more →PHATPhathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2024 Annual Meeting
Phathom Pharmaceuticals announced it will present data from studies of its treatment VOQUEZNA at the Digestive Disease Week 2024, including an oral presentation of its Phase 3 results for Non-Erosive Reflux Disease. The research will also cover real-world treatment patterns and healthcare resource utilization associated with Erosive GERD. The FDA has accepted Phathom's New Drug Application for VOQUEZNA, with a target action date of July 19, 2024. The conference, taking place in Washington, D.C., will feature multiple sessions highlighting the latest advances in gastrointestinal disorders.
Read more →PHATPhathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Over 17,500 total prescriptions for VOQUEZNA products have been dispensed, launch-to-date, a 361% increase since last quar
Phathom Pharmaceuticals has released its financial results for Q1 2024, indicating significant growth in the dispensation of its VOQUEZNA product for Erosive GERD, with a 361% increase in total prescriptions since last quarter. The CEO, Terrie Curran, expressed optimism about the treatment's reception among prescribers and patients. However, the company reported a considerable net loss, significantly higher than the previous year, raising concerns about its financial health amidst the positive sales figures. Overall, Phathom is focused on expanding VOQUEZNA's market presence and potential treatment options.
Read more →PHATPhathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
Phathom Pharmaceuticals, Inc. announced a live webcast scheduled for May 9, 2024, at 8:30 AM ET to report its first quarter 2024 financial results and provide a business update. This session will showcase the company’s ongoing efforts in the development of novel treatments for gastrointestinal disorders. The event will be accessible via the Phathom website and a recording will be available for 90 days post-event.
Read more →PHATPhathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Phathom Pharmaceuticals, Inc. has announced its participation in the 23rd Annual Needham Virtual Healthcare Conference, scheduled for April 10, 2024. The management team will take part in a fireside chat and conducting one-on-one meetings during the event, which runs from April 8 to 11, 2024. This conference offers Phathom an opportunity to showcase its innovative approaches in treating gastrointestinal diseases. The event is expected to be accessible via a live webcast on the company's website.
Read more →PHATPhathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
Phathom Pharmaceuticals has launched a Direct-to-Consumer campaign titled 'VOQUEZNA Can Kick Some Acid' to promote its novel treatment for Erosive GERD. The campaign aims to educate patients and encourage them to consult healthcare providers about VOQUEZNA, which has shown superior efficacy compared to conventional proton pump inhibitors. The treatment is positioned as a significant advance in GI disease management, as it is the first major innovation for Erosive GERD in over 30 years. The company is also providing savings programs for eligible patients to enhance treatment access.
Read more →PHAT▼ -6.6%on this news
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Launched VOQUEZNA (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal
Phathom Pharmaceuticals released its financial results for Q4 and the full year 2023, highlighting a transformative year marked by the launch of VOQUEZNA for the treatment of Erosive GERD. The company noted robust early demand and a positive reception from physicians and payers, indicating momentum for future growth. Additionally, the potential for VOQUEZNA's approval for Non-Erosive GERD could further expand market opportunities. However, Phathom faces challenges, including significant financial losses and reliance on third parties for their product development and commercialization.
Read more →PHATPhathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
Phathom Pharmaceuticals, Inc. has announced that it will report its fourth quarter and full year 2023 financial results on March 7, 2024. The event will include a live webcast at 8:30 a.m. ET, aimed at updating stakeholders on the company's recent business progress. Phathom is focused on treatments for gastrointestinal diseases, including the marketed vonoprazan. Further information can be found on the company’s website.
Read more →PHATPhathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
Phathom Pharmaceuticals announced that its drug VOQUEZNA (vonoprazan) has been added to the Express Scripts national formularies for commercial plans, effective immediately. VOQUEZNA is the first FDA-approved potassium-competitive acid blocker for treating Erosive GERD in over three decades. This formulary placement potentially provides access to 60 million covered lives in the US. Phathom aims to further increase coverage by engaging with additional pharmacy benefit managers.
Read more →PHATPhathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Phathom Pharmaceuticals, Inc. will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. The management team will take part in a fireside chat and one-on-one meetings during the event. This conference represents an opportunity for Phathom to engage with investors and discuss their novel treatments for gastrointestinal diseases, including the first-in-class drug vonoprazan.
Read more →PHAT▲ +8%on this news
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
Phathom Pharmaceuticals announced an amendment to its loan agreement with Hercules Capital, providing up to $300 million in total funding. Key updates include a 14-month extension of the interest-only period and the maturity date now set for December 2027. The company has also secured access to an additional $100 million in non-dilutive funding, contingent on meeting certain revenue milestones. The improvements are expected to offer Phathom sufficient cash flow to support its operations through the end of 2026.
Read more →PHAT▼ -5.4%on this news
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
Phathom Pharmaceuticals announced the FDA's acceptance for review of its New Drug Application for VOQUEZNA (vonoprazan), aimed at treating heartburn associated with Non-Erosive gastroesophageal reflux disease (GERD). The FDA has designated a 10-month review period, with a target action date set for July 19, 2024. The application includes positive Phase 3 trial results from the PHALCON-NERD-301 study, and a launch is expected in the third quarter of 2024, pending approval. The announcement highlights the significance of Non-Erosive GERD, which affects millions of adults in the U.S.
Read more →PHATPhathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
Phathom Pharmaceuticals has launched VOQUEZNA (vonoprazan), the first FDA-approved potassium-competitive acid blocker for Erosive GERD treatment. This novel medication is now available in U.S. pharmacies and promises rapid and effective acid suppression without mealtime dosing, addressing a high unmet need in the market. Clinical studies demonstrated VOQUEZNA's superior healing rates compared to traditional therapies. However, potential side effects, including gastrointestinal issues and serious health risks, warrant careful consideration by healthcare providers and patients.
Read more →PHATPhathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates VOQUEZNA (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of
Phathom Pharmaceuticals reported its third-quarter financial results and significant business updates, including the FDA approval of VOQUEZNA for treating Erosive GERD. The company's CEO highlighted the potential of their upcoming product launch scheduled for December. Additionally, Phathom submitted a New Drug Application for vonoprazan as a daily treatment for Non-Erosive GERD. While the company secured $175 million to support its operations, it faces challenges such as market acceptance and regulatory risks in conjunction with its product development efforts.
Read more →PHATPhathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
Phathom Pharmaceuticals has received FDA approval for VOQUEZNA (vonoprazan) tablets, marking a significant advance in the treatment of Erosive GERD, the first in over 30 years. The approval is based on positive results from the pivotal Phase 3 PHALCON-EE trial, where VOQUEZNA showed superior healing rates compared to traditional treatments. VOQUEZNA is expected to be commercially available in December 2023, and Phathom anticipates receiving $175 million to support the drug's launch. A conference call to discuss details will be held on November 2, 2023.
Read more →PHATPhathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
Phathom Pharmaceuticals has received FDA approval for the reformulated vonoprazan tablets, intended for the VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK to treat H. pylori infections in adults. The company is preparing for a commercial launch in December 2023, aligning this with a possible approval for vonoprazan for Erosive GERD. Positive outcomes from the Phase 3 PHALCON-HP trial support the efficacy of these treatment regimens, which are designed to tackle rising antibiotic resistance issues. The anticipated launch reflects Phathom's commitment to enhancing patient care in gastrointestinal diseases.
Read more →PHATPhathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
Phathom Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for vonoprazan as a daily treatment for Non-Erosive GERD, supported by positive results from the Phase 3 PHALCON-NERD-301 study. The submission aims to address a significant unmet need for approximately 38 million U.S. adults with Non-Erosive GERD. FDA decision is expected in Q3 2024, and Phathom also aims to begin a Phase 3 trial for episodic heartburn relief.
Read more →PHATPhathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
Phathom Pharmaceuticals has submitted six-month stability data to the FDA in support of its New Drug Application (NDA) for vonoprazan, a treatment for Erosive GERD. The data demonstrated that the nitrosamine impurity levels remain significantly below FDA limits, which supports the proposed product shelf life. This submission addresses previous concerns raised in a Complete Response Letter issued in February 2023. Phathom anticipates a planned commercial launch for the drug in the fourth quarter of 2023, contingent upon regulatory approval.
Read more →PHATPhathom Pharmaceuticals Reports Second Quarter 2023 Results Prior Approval Supplement (PAS) for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK assigned a Prescription Drug User Fee Act (PDUFA) goal date of
Phathom Pharmaceuticals has reported its second quarter 2023 financial results, highlighting significant progress in regulatory submissions and a successful capital raise of $141.4 million. The company is focused on preparing for upcoming product launches while addressing criteria set by the FDA regarding impurity levels. However, there are inherent risks concerning the consistency of data needed for regulatory approvals, as well as concerns about the company’s reliance on third-party partners. Overall, Phathom is actively pursuing its strategic objectives in the biopharmaceutical space.
Read more →PHATPhathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
Phathom Pharmaceuticals has announced that the FDA has accepted its New Drug Application (NDA) resubmission for vonoprazan, aimed at treating Erosive GERD. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date for November 17, 2023. This acceptance allows the FDA to continue reviewing the NDA following a previous complete response letter related to nitrosamine impurities. A combined launch for vonoprazan in both Erosive GERD and H. pylori indications is planned for Q4 2023, pending approval.
Read more →PHAT▲ +5.6%on this newsshared move
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
Phathom Pharmaceuticals announced the closing of an additional sale of 1,668,750 common shares at $11.75 each, completing a public offering that generated approximately $150.3 million in gross proceeds. These funds will be utilized for the clinical development and commercialization of their drug vonoprazan, among other corporate purposes. The offering was facilitated by Jefferies and Evercore ISI as joint bookrunning managers. The company also issued a caution regarding potential risks that may affect their plans and timelines.
Read more →PHATPHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Phathom Pharmaceuticals on behalf of the company's stockholders, focusing on potential violations of federal securities laws. The inquiry highlights a past incident where the company reported trace levels of a nitrosamine in its drug product, resulting in significant stock price decline and delayed product launches. Investors who have suffered losses are encouraged to contact the law firm for more information.
Read more →PHATPhathom Pharmaceuticals Announces Proposed Public Offering of Common Stock Florham Park, N.J.
Phathom Pharmaceuticals has announced a proposed public offering of common stock to raise funds for the clinical development of vonoprazan and associated expenses. The company intends to grant underwriters a 30-day option to purchase an additional 15% of shares offered. The success of the offering is contingent on market conditions, and there is no assurance regarding the timing or actual terms of the offering. This funding is part of Phathom's strategy to advance its novel treatments for gastrointestinal diseases.
Read more →PHATPhathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Phathom Pharmaceuticals announced the pricing of a public offering for 11,125,000 shares of common stock at $11.75 per share, expected to gross around $130.7 million. The proceeds will be used to fund clinical developments for vonoprazan and other corporate expenses. The offering is expected to close around May 26, 2023, pending customary conditions. The company emphasizes potential risks tied to market conditions and regulatory approvals that could affect the outcomes of their plans.
Read more →PHATPhathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
Phathom Pharmaceuticals has resubmitted its New Drug Application (NDA) for vonoprazan, a first-in-class treatment for Erosive GERD, after addressing FDA concerns from a previous Complete Response Letter. This resubmission includes three months of stability data demonstrating effective control of the impurity N-nitroso-vonoprazan. If approved, Phathom plans to launch this innovative treatment alongside H. pylori indications by the end of 2023. However, the approval process remains subject to the FDA's evaluation of ongoing data and potential risks associated with clinical development.
Read more →PHATPhathom Pharmaceuticals Reports First Quarter 2023 Results
Phathom Pharmaceuticals reported its financial results for Q1 2023, indicating significant advancements in developing vonoprazan for Erosive GERD and H. pylori infections. The company highlighted plans for a potential commercial launch by the end of 2023 and confidence in addressing previous FDA concerns regarding product formulation. However, potential risks include difficulties in producing stability data for nitrosamine levels and uncertainties surrounding the NDA resubmission process.
Read more →PHATPhathom Pharmaceuticals Presents New Data at Digestive Disease Week (DDW) 2023
Phathom Pharmaceuticals presented new data at Digestive Disease Week 2023, showcasing higher H. pylori eradication rates with vonoprazan-based therapies compared to traditional lansoprazole treatment. The Phase 3 PHALCON-HP trial underlined the drug's effectiveness across various demographics. Additionally, meta-analysis data indicated that potassium-competitive acid blockers such as vonoprazan exhibited prolonged pH control, leading to enhanced healing rates for Erosive GERD. Despite these promising results, potential regulatory and manufacturing challenges remain.
Read more →PHAT▼ -5.8%on this news
Phathom Pharmaceuticals, Inc: Company Investigated by the Portnoy Law Firm
Phathom Pharmaceuticals, Inc., is being investigated by the Portnoy Law Firm for possible securities fraud, and a class action lawsuit may be filed on behalf of investors. The investigation arises amid concerns surrounding the company's product, vonoprazan, which was found to have trace levels of a nitrosamine impurity during post-approval testing. This finding has contributed to delays in the product's market launch and a significant drop in the company's stock price. Investors who have suffered losses are encouraged to contact the law firm for assistance with their legal rights.
Read more →PHAT▲ +8.4%on this news
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
Phathom Pharmaceuticals announced a regulatory update regarding its erosive esophagitis NDA following favorable feedback from the FDA. The company plans to resubmit its NDA this quarter, aiming for a combined commercial launch of its treatments for erosive esophagitis and H. pylori indications in Q4 2023. Mitigation measures have been implemented to control a nitrosamine impurity, which were a previous concern raised by the FDA. The company remains optimistic about meeting the necessary requirements for approval but acknowledge risks with data generation and third-party dependencies.
Read more →PHAT▼ -11.8%on this news
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Meeting scheduled in March 2023 with the U.S. Food and Drug Administration (FDA) to discuss stability data
Phathom Pharmaceuticals reported its fourth quarter and full year 2022 financial results, detailing important advancements in the development of its gastrointestinal treatment vonoprazan. The company received FDA approval for its first products and is working on resolving a nitrosamine impurity issue that has temporarily stalled a commercial launch. A meeting with the FDA is scheduled for March to discuss the resubmission plan and potential review timelines, which may help expedite availability of vonoprazan to patients. Despite the progress, there remain significant risks related to product approval and stability data generation.
Read more →PHATPhathom Pharmaceuticals Provides Regulatory Updates
Phathom Pharmaceuticals, Inc. announced regulatory updates regarding its products, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, as well as its erosive esophagitis NDA. The FDA's complete response letters highlighted concerns over a nitrosamine impurity found in launch materials. Despite these challenges, Phathom's leadership remains optimistic about upcoming FDA discussions and their plans for resubmission. The company is confident that their data will pave the way for the approval and launch of important treatments.
Read more →PHATPhathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Phathom Pharmaceuticals has announced positive topline results from its Phase 3 PHALCON-NERD-301 trial, demonstrating that both 10 mg and 20 mg doses of vonoprazan significantly improved the percentage of heartburn-free days compared to placebo. The results provide a promising outlook for vonoprazan as a daily treatment for symptomatic non-erosive gastroesophageal reflux disease (NERD), which afflicts over 45 million people in the U.S. Following the completion of an ongoing safety extension period, full trial results are expected later this year. The data will support an FDA submission seeking approval for this novel therapy.
Read more →PHAT▼ -6.7%on this newsshared move
Phathom Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses
Phathom Pharmaceuticals, Inc. is facing investigations initiated by the Portnoy Law Firm for investors who lost money on their stock. This follows the FDA's notification that no action will be taken on the company's new drug application for vonoprazan before the PDUFA date. The FDA's decision comes in the wake of Phathom acknowledging trace levels of a nitrosamine impurity in its product. As a result, Phathom's stock price significantly declined.
Read more →PHAT▲ +6.9%on this news· ran to -33% by day 3shared move
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
Phathom Pharmaceuticals announced that the FDA will not take action on its new drug application for vonoprazan before the PDUFA target date of January 11, 2023. The FDA requested additional stability data related to a nitrosamine impurity detected in the product. Consequently, Phathom no longer anticipates launching vonoprazan for erosive esophagitis or H. pylori in early 2023, although they remain optimistic about ongoing label negotiations and the drug's potential in the market. The company is actively working to meet the FDA's requirements to move forward with the product.
Read more →PHATPhathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topli
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates FLORHAM PARK, N.J., November 8, 2022 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastr
Read more →PHATPhathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of its management t
Read more →PHATPhathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement Up to $40 million committed, resulting in total financing
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement FLORHAM PARK, N.J., November 1, 2022 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company foc
Read more →PHATPhathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
A total of 776 patients with symptomatic NERD have been enrolled and randomized in the multisite trial across the U.S. Topline data for the primary endpoint is expected in Q1 2023 with full trial results available in late-2023 NERD is the largest subcategory of gastroesophageal
Read more →PHATPhathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that detailed results from an in
Read more →PHATPhathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today the company will present new dat
Read more →PHATPhathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James “Jamie
Read more →PHATPhathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
FLORHAM PARK, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management
Read more →PHATPhathom Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) (NASDAQ: PHAT) investors that the firm has initiated a
Read more →PHAT▼ -28.8%on this newsshared move
Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates Erosive Esophagitis (EE) New Drug Application (NDA) accepted by U.S. Food and Drug Administration (FDA) with Prescriptio
Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates FLORHAM PARK, N.J., August 2, 2022 (GLOBE NEWSWIRE) Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel trea
Read more →PHATPhathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management t
Read more →PHAT▼ -5.2%on this news
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has
Read more →PHAT▼ -7.1%on this newsshared move
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week (DDW) 2022
Results from an investigational Phase 3 PHALCON-EE trial demonstrating superior healing at week 2 in patients with LA Grade C/D (moderate-to-severe) erosive esophagitis and superior maintenance of healing at week 24 in all patients with vonoprazan versus lansoprazole shared in or
Read more →PHAT▲ +21.5%on this news
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori (H. pylori) infection Phathom research recognized with multiple “posters of distinction” by Ame
Read more →PHAT▼ -8.1%on this news
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA TRIPLE PAK (vonoprazan, amo
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates FLORHAM PARK, N.J., May 10, 2022 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel
Read more →PHAT▼ -6.7%on this news· ran to -39% by day 3
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital FLORHAM PARK, N.J., May 4, 2022 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treat
Read more →PHATPhathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
VOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple therapy in the overall patient population of the pivotal Phase 3 trial1 VOQUEZ
Read more →PHAT▼ -5.1%on this news
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board o
Read more →PHATPhathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the manag
Read more →PHAT▲ +9.8%on this news
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly
Read more →PHAT▼ -10.5%on this news
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has submitted a n
Read more →PHATPhathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress FLORHAM PARK, N.J., March 1, 2022 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on de
Read more →PHATPhathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
Vonoprazan met the primary endpoint for all three dose levels (10 mg, 20 mg, 40 mg) taken on-demand, demonstrating faster and sustained relief of episodic heartburn as compared to placebo (p<0.0001) Phathom has commenced a Phase 3 NERD development program with the initiation of
Read more →PHATPhathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference
FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the manage
Read more →PHATPhathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its manage
Read more →PHATPhathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates Florham Park, N.J., November 08, 2021 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and c
Read more →PHATPhathom Pharmaceuticals Withdraws Public Offering
FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the withdrawal of the prev
Read more →PHATPhathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock
FLORHAM PARK, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today an underwritten public off
Read more →PHATPhathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical Research Phase 1 population PK data abstract concludes the large body of pre-existing clinical data related to vonoprazan in Asian populatio
Read more →PHATPhathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that data for vonoprazan,
Read more →PHAT▼ -16.1%on this newsshared move
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phases Vonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus lansoprazole (PREVACID®), a proton pump inhibitor (PPI) Vonoprazan demonstrate
Read more →PHATPhathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID )
Vonoprazan 20 mg demonstrated significantly greater acid suppressive effects over the 7-day study period compared to lansoprazole (PREVACID®) 30 mg, a proton pump inhibitor (PPI) FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),
Read more →PHATPhathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a $200 mil
Read more →PHATPhathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has submitted two
Read more →PHATPhathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, Presid
Read more →PHATPhathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones Pivotal Phase 3 PHALCON-EE trial topline data for vonoprazan in erosive esophagitis expecte
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones Florham Park, N.J., August 10, 2021 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developi
Read more →PHATPhathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka Tachi Yamada
Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka Tachi Yamada, M.D. FLORHAM PARK, N.J., August 5, 2021 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatmen
Read more →PHATPhathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, Phatho
Read more →PHATPhathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the managem
Read more →PHATPhathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates Positive Phase 3 trial of vonoprazan in Helicobacter pylori ( H. pylori ) infection; New Drug Applications (NDAs) targeted f
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates Florham Park, N.J., May 11, 2021 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatme
Read more →PHATPhathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the managem
Read more →PHATPhathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
Both vonoprazan-based treatment regimens demonstrated superior eradication rates vs. a standard of care proton pump inhibitor (PPI)-based triple therapy New Drug Application (NDA) submissions targeted for Q4 2021 Phathom to host conference call and live webcast today, April 29,
Read more →PHATPhathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the manag
Read more →PHATPhathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress FLORHAM PARK, N.J., March 30, 2021 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on develop
Read more →PHATPhathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
Topline results expected in second quarter of 2021 NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on develop
Read more →PHATPhathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock Florham Park, N.J.
Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock Florham Park, N.J., December 15, 2020 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel tre
Read more →PHATPhathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
FLORHAM PARK, N.J., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced plans to expand its vonopr
Read more →PHATPhathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
FLORHAM PARK, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed pati
Read more →PHATPhathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the manage
Read more →PHATPhathom Pharmaceuticals to Host Virtual Investor Day
Event to be webcast on Monday, December 14, 2020 at 1:00 PM (ET) FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gas
Read more →PHATPhathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the manage
Read more →PHATPhathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials Pivotal Phase 3 PHALCON-EE trial enrollment expected to complete before year-end 2020; top-line results expected in the sec
Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials Florham Park, N.J., November 10, 2020 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel t
Read more →PHATPhathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference
FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the manag
Read more →PHATPhathom Pharmaceuticals Reports Second Quarter 2020 Results Florham Park, N.J.
Phathom Pharmaceuticals Reports Second Quarter 2020 Results Florham Park, N.J., August 6, 2020 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases,
Read more →PHATPhathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer
FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has appointed Todd
Read more →PHATPhathom Pharmaceuticals Provides Clinical Trial Status Update
FLORHAM PARK, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has randomized the
Read more →PHATPhathom Pharmaceuticals to Present at Upcoming Investor Conferences
FLORHAM PARK, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, Preside
Read more →PHATPhathom Pharmaceuticals Reports First Quarter 2020 Results Florham Park, N.J.
Phathom Pharmaceuticals Reports First Quarter 2020 Results Florham Park, N.J., May 12, 2020 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, to
Read more →PHATPhathom to Participate at the 19th Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that company management w
Read more →PHATPhathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates Successfully Finished 2019 with Initiation of Two Pivotal Phase 3 Trials for Vonoprazan in Erosi
Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates Florham Park, N.J., March 19, 2020 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing an
Read more →PHATPhathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020
FLORHAM PARK, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that Terrie Curran, Presid
Read more →PHATPhathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update BUFFALO GROVE, Ill., November 25, 2019 Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing nov
Read more →Competitive Position
How PHAT ranks across every disease it competes inCompetitive Position is a premium feature
See how PHAT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial